|
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. |
|
|
Research Funding - Progenics (Inst) |
|
|
Stock and Other Ownership Interests - Precision Molecular |
Research Funding - Progenics (Inst) |
Travel, Accommodations, Expenses - Progenics |
|
|
Leadership - CUE Biopharma; Keystone Biopharma |
Stock and Other Ownership Interests - CUE Biopharma; Keystone Biopharma; Medsyn Biopharma; Oncopia Therapeutics |
Consulting or Advisory Role - Akrevia Therapeutics; CUE Biopharma; GloriousMed Technology |
Research Funding - Progenics |
Travel, Accommodations, Expenses - CUE Biopharma |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Genzyme; Janssen |
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Ferring; Genzyme; Janssen; Pfizer; Progenics; Sanofi; Sanofi |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst); TerSera (Inst) |
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection |
Other Relationship - Merck; Progenics |
|
|
Honoraria - Advanced Accelerator Applications; Bayer; POINT Biopharma |
Consulting or Advisory Role - Advanced Accelerator Applications; Lantheus Medical Imaging |
Research Funding - Lantheus Medical Imaging; POINT Biopharma |
|
|
Research Funding - Progenics (Inst) |
|
|
|
Consulting or Advisory Role - Bayer |
|
Travel, Accommodations, Expenses - Koelis |
|
|
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer |
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Merck |
|
|
Stock and Other Ownership Interests - Gilead Sciences; Roche/Genentech |
Honoraria - American Physician Institute; Exelixis; Healthcasts; Medscape; Prime Oncology |
Consulting or Advisory Role - Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy |
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Progenics (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Consulting or Advisory Role - AVID Radiopharmaceuticals; Capella Imaging; Curium Pharma; ImaginAb; Progenics |
Research Funding - American College of Radiology (Inst); Blue Earth Diagnostics (Inst); Curium Pharma (Inst); ImaginAb (Inst); Progenics (Inst) |
|
|
Stock and Other Ownership Interests - Doximity |
Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Endocyte; Exelixis; Johnson & Johnson; Lantheus Medical Imaging; NCCN; Novartis; ORIC Pharmaceuticals; Progenics |
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Endocyte; Fujifilm |